Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Royalty Pharma plc - Class A Ordinary Shares (NQ: RPRX )

32.85 +0.39 (+1.20%)
Official Closing Price Updated: 4:15 PM EDT, Mar 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,447,282
Open 32.31
Bid (Size) 32.26 (1)
Ask (Size) 34.00 (1)
Prev. Close 32.46
Today's Range 32.00 - 32.91
52wk Range 24.05 - 34.20
Shares Outstanding 388,132,400
Dividend Yield 2.56%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Is ROYALTY PHARMA PLC- CL A (NASDAQ:RPRX) Ready to Break Out of Its Range?
Exploring ROYALTY PHARMA PLC- CL A's Technical Signals and Breakout Potential: Based on good technical signals, ROYALTY PHARMA PLC- CL A is potentially setting up for a breakout. 
Via Chartmill
1 Stock Under $50 with Exciting Potential and 2 to Ignore
Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than penny stocks. But their headline prices don’t guarantee quality, and... 
Via StockStory

Performance

YTD
+27.37%
+27.37%
1 Month
+3.56%
+3.56%
3 Month
+30.36%
+30.36%
6 Month
+18.25%
+18.25%
1 Year
+8.24%
+8.24%

More News

Read More
Q4 Earnings Outperformers: Corcept (NASDAQ:CORT) And The Rest Of The Branded Pharmaceuticals Stocks
Via StockStory
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
Royalty Pharma to Present at TD Cowen’s 45th Annual Health Care Conference
From Royalty Pharma plc
Via GlobeNewswire
Peering Into Royalty Pharma's Recent Short Interest
Via Benzinga
Biogen Q4 Earnings: Revenue And EPS Beat, Warns Lower 2025 Revenue, Inks R&D Funding Pact With Royalty Pharma
Via Benzinga
Royalty Pharma Announces R&D Funding Collaboration With Biogen
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma (NASDAQ:RPRX) Misses Q4 Revenue Estimates
Via StockStory
Royalty Pharma Reports Q4 and Full Year 2024 Results
From Royalty Pharma plc
Via GlobeNewswire
US Stocks Dip As Powell Stays Cautious, Intel Climbs, Tesla Sinks To 11-Week Low: What's Driving Markets Tuesday?
Via Benzinga
Royalty Pharma Earnings: What To Look For From RPRX
Via StockStory
Earnings Scheduled For February 11, 2025
Via Benzinga
Royalty Pharma Announces Sale of MorphoSys Development Funding Bonds
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma to Announce Fourth Quarter and Full Year 2024 Financial Results on February 11, 2025
From Royalty Pharma plc
Via GlobeNewswire
Cytokinetics Heart Drug's Future Sparks Optimism Despite M&A Hurdles and Royalty Deal Concerns: Analyst
Via Benzinga
Walgreens Boots Alliance, Aurora Innovation And Delta Air Lines Are Among Top Large Cap Gainers Last Week (Jan 6-10): Are The Others In Your Portfolio?
Via Benzinga
TD Synnex, Walgreens, Savers Value Village And Other Big Stocks Moving Higher On Friday
Via Benzinga
Royalty Pharma to Highlight Accomplishments and Provide Business Update at 43rd Annual J.P. Morgan Healthcare Conference
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma Announces Transformative Step in Company’s Evolution With Acquisition of its External Manager and $3 Billion Share Repurchase Program
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma Announces Dividend Increase
From Royalty Pharma plc
Via GlobeNewswire
Jim Cramer Likes Walmart, Recommends Buying This 'Very, Very Good' Financial Stock
Via Benzinga
3 High-Yield Dividend Stocks to Buy in 2025 and Hold for a Decade or Longer
Via The Motley Fool
2 Exceptional Dividend Stocks Near 52-Week Lows You Could Regret Not Buying on the Dips
Via The Motley Fool
3 High-Yield Dividend Growth Stocks to Buy in December and Hold for a Decade or Longer
Via The Motley Fool
Royalty Pharma to Present at Upcoming Investor Conferences
From Royalty Pharma plc
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS